Objective: The overall use of intensive care units (ICUs) in the United States has been steadily increasing and is typically associated with tremendous health care costs. Knowledge about the routine use of ICUs after vascular operations is currently lacking. Therefore, we sought to identify the burden of ICU utilization after elective infrainguinal lower extremity bypass (LEB) in patients with intermittent claudication (IC).
VESS16.

Iliac Vein Stent Placement and the Iliocaval Confluence
Objective: Prior literature has recommended routine iliac vein stent extension into the inferior vena cava (IVC) to ensure adequate outflow for iliac vein stenting procedures. Our bias was only the lesion to be stented without routine stent extension up to the IVC. We report our experience with this limited stenting technique.
Methods: From 2012 to 2015, there were 844 patients (1216 limbs) who underwent iliac vein stenting for nonthrombotic iliac vein lesions. All limbs were classified according to the presenting sign of the Clinical, Etiology, Anatomy, and Pathophysiology (CEAP) score, duplex ultrasound scans, and intravascular ultrasound showing >50% cross-sectional area or diameter reduction. All study patients had failed to respond to conservative management. The procedures of iliac vein stenting were all office based. Two techniques were compared: placement of the iliac vein stent to cover the lesion and terminating cephalad into the IVC if the lesion involved the common iliac vein; and placement of the iliac vein stent to cover the lesion only and not passing the iliocaval confluence if the lesion involved only the external iliac vein. Complications were assessed during 30 days of followup using duplex ultrasound scan to look for thrombosis.
Results: The average age was 66 (614.2) years (range, 21-99 years), and 773 were women. The stent was placed in the left lower limb in 661 patients and bilaterally in 368 patients. The presenting sign according to CEAP classification was as follows: C3, 503; C4, 572; C5, 85; and C6, 56 . The average iliac vein stenosis was 62% (6 12% standard deviation). We had 715 patients with the iliac vein stent extending into the IVC, and of these, 22 patients had thrombosis within 30 days after the procedure. On the other hand, 501 patients had the iliac vein stent without crossing the iliocaval confluence, and of these, 16 patients had thrombosis within 30 days of the procedure. There was no difference between these two groups in regard to sex (P ¼ .1) or age (P ¼ .2). Comparing these two groups in regard to 30-day thrombosis as a complication was not statically significant (P ¼ .9). Conclusions: These results question the need for routine iliac vein stent extension into the IVC. We were not able to demonstrate a significant risk of thrombosis with just placing the stent to cover the lesion only with short-term follow-up. This approach may simplify the procedure and result in significant cost savings.
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IF: INTERNATIONAL FORUM
Methods: We selected patients with preprocedural strokes undergoing nonemergent carotid endarterectomy (CEA) and carotid stenting (CAS) in the Vascular Quality Initiative between 2012 and 2017. We evaluated the risk of in-hospital stroke and 30-day mortality for expedited (<1 month) vs delayed (1 month) revascularization using multilevel logistic regression.
Results: Of 12,520 patients with an index stroke, 10,127 (81%) underwent CEA and 2393 (19%) underwent CAS. Of CEA patients, 56% (n ¼ 5668) underwent expedited revascularization compared with 59% (n ¼ 1402) for CAS (P ¼ .02). After adjustment, expedited revascularization in CEA patients was associated with a higher odds of stroke compared with delayed revascularization (odds ratio [OR] (OR, .5]; P < .001). Among patients with expedited revascularization, CAS patients experienced a similar stroke risk to that of CEA patients (OR,1.4 [0.9-2.2]; P ¼ .1) but a higher mortality risk (OR, 2.2 [1.4-3.5]; P ¼ .001), whereas among those undergoing delayed revascularization, CAS was associated with stroke (OR, 2.6 [1.5-4.4]; P < .001) but not with mortality (OR, 0.2 [0.03-1.6]; P ¼ .1). In addition, patients with a major index stroke experienced a stroke/death rate of 11% after expedited CAS vs 5.7% after expedited CEA (P ¼ .005).
Conclusions: Symptomatic patients undergoing expedited CEA or CAS after their index stroke experienced a higher procedural risk than those undergoing delayed revascularization. However, CAS was associated with higher procedural risk than CEA, especially among those undergoing revascularization <1 month of the index stroke.
